Ecopipam, a selective D1 antagonist in development for the treatment of Tourette syndrome in children and adolescents: The Phase 2b D1AMOND Study
Objective: To describe the Phase 2b study design and optimized dosing strategy to evaluate the efficacy and safety of ecopipam in children and adolescent subjects…The dopamine receptor antagonist haloperidol enhances beta and gamma oscillations and bursts in the motor cortex
Objective: We aimed to investigate the changes in oscillatory activity in the motor cortex (MCtx) and the sensorimotor cortex (SMCtx) of rats after acute injection…Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model
Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…Deep Brain Stimulation in Tourette Syndrome: Two illustrative cases
Objective: To describe two cases of patients with pharmacological refractory Tourette syndrome who underwent DBS in a single center in Bogota Colombia from 2012 -2015.…Drug-induced movement disorders: not a typical problem
Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome
Objective: To investigate the efficacy and safety of the selective dopamine D1 receptor antagonist ecopipam in children and adolescents with Tourette Syndrome (TS). Background: Dysregulation…Oculogyric Crisis Due to Treatment With flunarizine
Objective: To report the first case of oculogyric crisis (OC) secondary to flunarizine. Background: Oculogyric crisis (OC) are an infrequent neurologic complication of dopamine antagonists…Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease
Objective: To evaluate the impact of comorbidities and compliance iniciatives on treatment efficacy in patients with Parkinson's disease. Methods: In the year 2014 we included…Incidental finding of drug-induced movement disorder
Objective: Recognizing a drug-induced movement disorder is critical as only stopping using over the counter dopamine-blocking medications such as metoclopramide can reverse or improve clinical…A survey of movement disorders in a large sample of patients treated with antipsychotic medication
Objective: To describe the prevalence and nature of movement disorders (MD) in a large sample of patients treated with antipsychotic medication. Background: Although there are…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.